Roivant Sciences (ROIV) CFO Richard Pulik Sells $67K of Stock

CFO Richard Pulik Sells Shares of Roivant Stock

Roivant Sciences Ltd. Chief Financial Officer Richard Pulik parted with 2,129 shares of the company's stock on June 20, 2026. The shares were disposed of at a price of $31.43 each, bringing the total value of the transaction to $66,914.47. Regulatory filings show the trade was coded as a transaction type F, which typically covers shares withheld to cover tax obligations related to equity awards.

Recent Executive Stock Activity

This sale adds to a busy stretch of insider transactions at the clinical-stage biopharmaceutical firm. On June 25, 2026, President and CIO Mayukh Sukhatme exercised 500,000 options at $3.85 per share before selling 500,000 shares at an average price of $34.13 for a total of $17.06 million. Just a day earlier on June 24, 2026, President Eric Venker bought 200,000 shares for $770,000 and disposed of an equal number of shares. Chief Accounting Officer Jennifer Humes also sold 3,582 shares at $31.43 on June 20, 2026, matching the price and date of the CFO's transaction.

ROIV Stock Performance and Market Position

Shares of Roivant trade on the NasdaqGS under the ticker ROIV. The stock has moved between a 52-week low of $14.50 and a 52-week high of $42.50 over the past year. With no positive earnings per share currently recorded, the company lacks a traditional price-to-earnings multiple. The firm operates with a strong liquidity profile, featuring a current ratio well above ten, giving it financial flexibility as its clinical programs advance.

Wall Street Analyst Outlook

Analysts covering the biotech firm maintain a favorable view overall, anchored by a consensus recommendation of strong buy. Recent updates include Wolfe Research downgrading the stock to a Peer Perform rating on October 12, 2026. Earlier in the autumn, Stifel initiated coverage with a buy rating and a $51.00 price target on September 17, 2026, while TD Cowen maintained its buy rating and raised its target to $55.00 on September 9, 2026.

Clinical Pipeline and Corporate Focus

Roivant Sciences focuses on developing and commercializing medicines and drug delivery technologies across immunology and other therapeutic areas. Its clinical pipeline features candidates such as IMVT-1402 and mosliciguat targeting various autoimmune and pulmonary conditions. Executive transactions draw attention as leadership teams manage their personal equity holdings while advancing these multi-product clinical pipelines.

What to Watch Next for ROIV Stock

Investors will continue to monitor insider Form 4 filings alongside upcoming clinical data updates from the company's various drug programs. Roivant is scheduled to report its next round of earnings on November 9, 2026, which will provide fresh insight into the firm's financial burn rate and clinical milestones.